SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?


To: BDR who wrote (3249)8/24/1999 10:13:00 PM
From: DanZ  Read Replies (2) | Respond to of 10293
 
Dale,

With regard to your comment:

<I am only posting the fact that publication has not occurred yet because for a while the longs were repeatedly bringing up the mere submission of the article to the NEJM as evidence of the legitimacy of the product.>

I agree that one should not conclude that Zicam is a legitimate product simply because the study results were submitted to the NEJM. I have no doubt that many articles submitted to the NEJM are discarded either because the science isn't legitimate or the results don't meet the high standards of the Journal. I brought up the NEJM partly because somebody said the study hadn't undergone pier review, and partly because anyone considering a position in the stock might have wanted to know. Even though Zicam has worked for me personally, I can understand why many people would wait to see if the NEJM publishes the article before they accept it as a legitimate product.

Most of us can probably agree that Zicam's efficacy will be proven if the study is accepted by the NEJM. However, by his own admission Bill will ignore the importance of pier review, discard the reputation of the NEJM, call Zicam quack medicine because of it's label, and "short every up tick" out of spite. Did you know that a living faction of people still exist who think the Earth is flat? No matter what evidence is put before some people, they just refuse to believe.

Best of luck to everyone,

Dan